MY156536A - Inhibitors of protein tyrosine kinase activity - Google Patents

Inhibitors of protein tyrosine kinase activity

Info

Publication number
MY156536A
MY156536A MYPI2010000797A MYPI20100797A MY156536A MY 156536 A MY156536 A MY 156536A MY PI2010000797 A MYPI2010000797 A MY PI2010000797A MY PI20100797 A MYPI20100797 A MY PI20100797A MY 156536 A MY156536 A MY 156536A
Authority
MY
Malaysia
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
receptor signalling
inhibitors
Prior art date
Application number
MYPI2010000797A
Other languages
English (en)
Inventor
Claridge Stephen William
Vaisburg Arkadii
Uno Tetsuyuki
Raeppel Stéphane
Isakovic Ljubomir
Mannion Michael
Saavedra Oscar Mario
Gaudette Frédéric
Zhan Lijie
Nancy Z Zhou
Raeppel Franck
Déziel Robert
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of MY156536A publication Critical patent/MY156536A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MYPI2010000797A 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity MY156536A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29

Publications (1)

Publication Number Publication Date
MY156536A true MY156536A (en) 2016-02-26

Family

ID=40386626

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010000797A MY156536A (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Country Status (19)

Country Link
US (3) US8404846B2 (cg-RX-API-DMAC7.html)
EP (1) EP2183254B1 (cg-RX-API-DMAC7.html)
JP (1) JP5656634B2 (cg-RX-API-DMAC7.html)
KR (1) KR101556269B1 (cg-RX-API-DMAC7.html)
CN (3) CN101932586A (cg-RX-API-DMAC7.html)
AR (1) AR068066A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008293038B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816064B8 (cg-RX-API-DMAC7.html)
CA (1) CA2697795C (cg-RX-API-DMAC7.html)
DK (1) DK2183254T3 (cg-RX-API-DMAC7.html)
ES (1) ES2635131T3 (cg-RX-API-DMAC7.html)
IL (1) IL204192A (cg-RX-API-DMAC7.html)
MX (1) MX2010002427A (cg-RX-API-DMAC7.html)
MY (1) MY156536A (cg-RX-API-DMAC7.html)
PL (1) PL2183254T3 (cg-RX-API-DMAC7.html)
RU (1) RU2495044C2 (cg-RX-API-DMAC7.html)
TW (1) TWI571468B (cg-RX-API-DMAC7.html)
WO (1) WO2009026717A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001512B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2763168A1 (en) * 2008-03-05 2009-09-11 Michael Mannion Inhibitors of protein tyrosine kinase activity
KR20110075016A (ko) 2008-10-14 2011-07-05 닝 시 화합물 및 사용 방법
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US8809534B2 (en) 2009-09-03 2014-08-19 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
EP2563795A4 (en) * 2010-04-16 2013-10-23 Methylgene Inc Inhibitors of protein intolerance activity
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CA2812753A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
JP2013537918A (ja) * 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
EP3227276B1 (en) 2014-12-02 2021-09-01 Ignyta, Inc. Combinations for the treatment of neuroblastoma
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
CA3008663A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations of a selective tyrosine kinase inhibitor (tki) with a mek or erk inhibitor for the treatment of cancer
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN111295386B (zh) * 2018-03-08 2022-09-06 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
CN112771053A (zh) 2019-09-06 2021-05-07 伟迈可生物有限公司 基于生物标志物的治疗组合物
WO2021050580A1 (en) * 2019-09-10 2021-03-18 Mirati Therapeutics, Inc. Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
WO2021098769A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
CN114945576B (zh) * 2020-01-07 2023-10-13 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
US20230321062A1 (en) 2020-09-17 2023-10-12 Mirati Therapeutics, Inc. Combination therapies
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof
TW202342426A (zh) * 2022-02-15 2023-11-01 大陸商百濟神州（蘇州）生物科技有限公司 N-[(6-溴吡啶-3-基)甲基]-2-甲氧基乙烷-1-胺鹽及其製備方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
AU7340096A (en) 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
PL209822B1 (pl) 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
CN1906167A (zh) 2004-02-27 2007-01-31 卫材株式会社 新型吡啶衍生物及嘧啶衍生物(2)
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2005222627A1 (en) * 2004-03-15 2005-09-29 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives for inhibiting angiogenesis
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
BRPI0513982A (pt) 2004-07-30 2007-11-27 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
KR101378716B1 (ko) 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
EP1989211A2 (en) * 2006-01-30 2008-11-12 Array Biopharma, Inc. Heterobicyclic thiophene compounds for the treatment of cancer
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
WO2007146824A2 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US20100016307A1 (en) 2006-10-27 2010-01-21 Toshihiro Hamajima Novel compounds
EP2563795A4 (en) * 2010-04-16 2013-10-23 Methylgene Inc Inhibitors of protein intolerance activity

Also Published As

Publication number Publication date
JP2010536887A (ja) 2010-12-02
CN101932586A (zh) 2010-12-29
TW200914458A (en) 2009-04-01
AU2008293038B2 (en) 2013-08-29
AR068066A1 (es) 2009-11-04
CN105777776B (zh) 2021-06-08
RU2010111729A (ru) 2011-10-10
EP2183254B1 (en) 2017-06-21
US20120108628A1 (en) 2012-05-03
CN105777776A (zh) 2016-07-20
CN109970759A (zh) 2019-07-05
JP5656634B2 (ja) 2015-01-21
KR101556269B1 (ko) 2015-09-30
ZA201001512B (en) 2010-11-24
RU2495044C2 (ru) 2013-10-10
US20090264440A1 (en) 2009-10-22
WO2009026717A1 (en) 2009-03-05
AU2008293038A1 (en) 2009-03-05
DK2183254T3 (en) 2017-09-11
MX2010002427A (es) 2010-03-30
BRPI0816064A2 (pt) 2015-03-31
EP2183254A1 (en) 2010-05-12
TWI571468B (zh) 2017-02-21
CA2697795A1 (en) 2009-03-05
US20130165477A1 (en) 2013-06-27
BRPI0816064B8 (pt) 2021-05-25
PL2183254T3 (pl) 2017-10-31
BRPI0816064B1 (pt) 2020-01-28
KR20100075873A (ko) 2010-07-05
ES2635131T3 (es) 2017-10-02
IL204192A (en) 2016-08-31
US8846927B2 (en) 2014-09-30
EP2183254A4 (en) 2011-09-28
US8404846B2 (en) 2013-03-26
CA2697795C (en) 2016-08-16
US8389541B2 (en) 2013-03-05

Similar Documents

Publication Publication Date Title
MY156536A (en) Inhibitors of protein tyrosine kinase activity
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
UA100262C2 (uk) Інгібітори активності протеїнтирозинкінази
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
MX2010006739A (es) Compuestos pirido[2,3-b]pirazina-8-sustituidos y su uso.
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
UA96045C2 (ru) Амидное производное для ингибирования роста раковых клеток
NO20080162L (no) Tienopyrimidin og tienopyrimidinderivater som FLT-3 kinaseinhibitorer
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
MX342873B (es) Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa.
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
MY157319A (en) Inhibitors of protein tyrosine kinase activity
TN2018000078A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MX2012000166A (es) Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos.
EP1973407A4 (en) SPIRO COMPOUNDS AND METHODS OF USE
WO2008008310A3 (en) Tyrosine kinase inhibitors
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
TN2010000029A1 (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
NO20080174L (no) Alkylquinolin- og alkylquinazolinkinasemodulatorer
CR20210544A (es) DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2
SI1896421T1 (sl) Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met